Merck Issues Statement Regarding CUBICIN Patent Litigation; Says Reviewing Decision, Considering Next Steps

Merck MRK, known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit. The decision validated the patent for CUBICIN® (daptomycin for injection) that expires on June 15, 2016, but invalidated four patents with expiration dates in 2019 and 2020. The company is reviewing the decision and is considering its next steps, which may include seeking further review at the Federal Circuit or Supreme Court. About Merck Today's Merck is a global health care leader working to help the world be well. Merck is known See full press release